Highlight 5 in breast cancer
8 June 2023
Dr. Guilherme Nader Marta recently shared his insights on the most noteworthy presentations from the poster discussion session on metastatic breast cancer.
From 2 June till 6 June 2023: HIGHLIGHTS FROM ASCO – BREAST CANCER
Your direct line with Chicago
The American Society of Clinical Oncology (ASCO) 2023 brings together leading experts in the different fields of cancer from around the world. And, as usual, they gather together in Chicago, USA. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
With the educational support of:
Daily highlights in breast cancer
Highlight 4 in breast cancer
7 June 2023
Dr. Elisa Agostinetto, medical oncologist at the Institute Jules Bordet in Brussels shares her highlights from the poster discussion session on local/regional/adjuvant treatment for breast cancer.
Highlight 3 in breast cancer
6 June 2023
Prof. François Duhoux from Cliniques Universitaires St Luc in Brussels shares his insights on the most exciting presentations in the oral abstract session on metastatic breast cancer.
Highlight 2 in breast cancer
5 June 2023
Dr. Laure-Anne Teuwen, medical oncologist at the university hospital of Antwerp highlighted a population-based study evaluating the prognosis and trends in chemotherapy use for patients with stage IA triple-negative breast
Highlight 1 in breast cancer
3 June 2023
Today marks the start of the ASCO 2023 congress, with the first oral abstract session focusing on local, regional, and adjuvant treatment for breast cancer.
In-depth stories about breast cancer
Liquid biopsy to predict response to therapy in GeparNuevo trial
10 June 2023
Hanna Hübner from the University Hospital in Erlangen is investigating the RNA phenotype of peripheral immune cells in patients enrolled in the GeparNuevo trial for early-stage breast cancer. By studying
Dr Elisa Agostinetto meets Dr Guilherme Nader Marta
9 June 2023
In this interview, we bring together two ASCO award winners, both working at the Institut Jules Bordet in Brussels, to discuss their winning abstracts in front of the camera.
Early-Stage Triple-Negative Breast Cancer
8 June 2023
MediMix had the privilege of consulting with two experts, Prof Duhoux from Cliniques Universitaires St Luc and Prof Evandro De Azambuja from the Institute Jules Bordet, to provide insights on
DESTINY-BREAST 01, -02, -03: Age-specific pooled analysis
7 June 2023
Trastuzumab deruxtecan (T-DXd) has been approved for the treatment of HER2-positive unresectable or metastatic breast cancer in patients who have received prior anti-HER2 therapy in the metastatic or (neo)adjuvant setting.
AURORA PROGRAM: Messages for the daily clinic
6 June 2023
The benefit of immunotherapy in patients with metastatic breast cancer is primarily observed in those with triple negative breast cancer and PD-L1 expression in the tumor sample. To gain a
Breast cancer poster selection
NeoRhea phase II study – secondary analysis on ctDNA monitoring
6 June 2023
The NeoRhea study is a phase 2 clinical trial that focuses on patients with estrogen receptor-positive/HER2-negative early breast cancer. The treatment approach involves administering neoadjuvant palbociclib in combination with endocrine
MammaPrint Index as a predictive biomarker
6 June 2023
Genomic signatures have shown promise in predicting the pathological complete response and treatment benefits of neoadjuvant chemotherapy in early breast cancer more accurately than traditional subtyping methods. The 70-gene MammaPrint
The PalomAGE study
6 June 2023
The standard treatment for hormone receptor-positive HER2-negative advanced breast cancer involves combining endocrine therapy with a CDK4/6 inhibitor. However, clinical trials often underrepresent women aged 70 and older, despite this